# Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

> **NCT03041285** · PHASE1 · TERMINATED · sponsor: **Royal North Shore Hospital** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Castrate- Resistant Prostate Cancer

## Interventions

- **DRUG:** idronoxil (NOX66) suppository
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03041285
- **Lead sponsor:** Royal North Shore Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-31
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-09-17
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** have difficulty finding eligible participants
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041285, "Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03041285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*